Skip to main content
. Author manuscript; available in PMC: 2016 Aug 18.
Published in final edited form as: Breast Cancer Res Treat. 2015 Mar 15;150(2):457–466. doi: 10.1007/s10549-015-3314-6

Table 2.

Weights based on 208 breast cancer cases from the Polish breast cancer study for the 57 genes identified from methylation analysis that have corresponding mRNA expression data and used as weighting factors for calculation of prognostic signature

Gene Gene name weights
DNALI1 dynein, axonemal, light intermediate chain 1 0.7370
CALML5 calmodulin-like 5 0.6845
HCLS1 hematopoietic cell-specific Lyn substrate 1 0.6748
SERPINA5 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5 0.6397
PDZK1 PDZ domain containing 1 0.6325
AGR3 anterior gradient 3 0.6307
PLAT plasminogen activator, tissue 0.6215
SCUBE2 signal peptide, CUB domain, EGF-like 2 0.6146
KYNU kynureninase 0.6116
SCNN1A sodium channel, non-voltage-gated 1 alpha subunit 0.5683
SPOCK2 sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 2 0.5480
REEP6 receptor accessory protein 6 0.5400
STC2 stanniocalcin 2 0.5338
C8orf4 chromosome 8 open reading frame 4 0.5319
CAP2 CAP, adenylate cyclase-associated protein, 2 (yeast) 0.5118
CFB complement factor B 0.5039
C1orf64 chromosome 1 open reading frame 64 0.5024
IL20 interleukin 20 0.4972
CD247 CD247 molecule 0.4967
FABP7 fatty acid binding protein 7, brain 0.4952
CCND1 cyclin D1 0.4827
AKR7A3 aldo-keto reductase family 7, member A3 (aflatoxin aldehyde reductase) 0.4678
TFF1 trefoil factor 1 0.4575
TAP1 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 0.4360
ZG16B zymogen granule protein 16B 0.4226
MMP7 matrix metallopeptidase 7 (matrilysin, uterine) 0.3514
HMGCS2 3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial) 0.3425
CAMK2N1 calcium/calmodulin-dependent protein kinase II inhibitor 1 0.3393
GZMA granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3) 0.3298
ATP6V1B1 ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B1 0.3214
GLIPR2 GLI pathogenesis-related 2 0.3054
PRSS8 protease, serine, 8 0.2737
MLPH melanophilin 0.2733
C10orf116 adipogenesis regulatory factor 0.2715
THRSP thyroid hormone responsive 0.2706
CRYAB crystallin, alpha B 0.2598
ALOX5AP arachidonate 5-lipoxygenase-activating protein 0.2439
IFITM3 interferon induced transmembrane protein 3 0.2414
CD248 CD248 molecule, endosialin 0.2359
CXCL12 chemokine (C-X-C motif) ligand 12 0.2344
SERPINA3 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 0.2328
CILP cartilage intermediate layer protein, nucleotide pyrophosphohydrolase 0.2233
CST3 cystatin C 0.2154
HLA-DRA major histocompatibility complex, class II, DR alpha 0.2039
SCGB3A1 secretoglobin, family 3A, member 1 0.1925
S100A7 S100 calcium binding protein A7 −0.1892
SLPI secretory leukocyte peptidase inhibitor 0.1823
GP1BB glycoprotein Ib (platelet), beta polypeptide −0.1781
S100A9 S100 calcium binding protein A9 0.1761
CCL8 chemokine (C-C motif) ligand 8 −0.1726
SMOC2 SPARC related modular calcium binding 2 0.1738
TFF3 trefoil factor 3 (intestinal) 0.1617
MSLN mesothelin 0.1611
MUC1 mucin 1, cell surface associated 0.1539
PRSS23 protease, serine, 23 0.1518
TMEM119 transmembrane protein 119 0.1026
PI15 peptidase inhibitor 15 0.1024

*These genes had more than one methylation marker associated with the mRNA expression target and the average of the sites was used to calculate the weighted Rho value.